Medical Oncologist
Bile duct cancer treatment
Targeted Therapy for — Bile Duct Cancer (Cholangiocarcinoma)
Bile duct cancer is one of the cancer types where specific gene mutations can now be matched to a targeted drug. The first step is knowing which mutations your tumour carries — and that answer comes from a genomic test, not from the diagnosis alone.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Testing finds the mutation — A single next-generation sequencing test on your biopsy tissue checks for all known actionable mutations at once.
- Multiple targets now have drugs — FGFR2, IDH1, NTRK, and BRAF are among the mutations with approved targeted treatments in cholangiocarcinoma.
- Location matters — FGFR2 and IDH1 mutations are most common in intrahepatic cholangiocarcinoma — the type that starts inside the liver.
- No mutation found is not the end — Chemotherapy and clinical trials remain options if genomic testing does not reveal a matched target.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Targeted therapy for cholangiocarcinoma works by blocking specific gene mutations rather than attacking all dividing cells. NCCN and ESMO recommend comprehensive genomic testing for all patients with advanced disease. A meaningful proportion carry mutations in FGFR2, IDH1, NTRK, or BRAF that now have approved targeted treatments.
Which gene mutations are tested in bile duct cancer?
NCCN and ESMO guidance recommends comprehensive genomic profiling — commonly called next-generation sequencing or NGS — for all patients with advanced cholangiocarcinoma at diagnosis. This test is done on tissue from your existing biopsy, so a new procedure is usually not needed.
The mutations with the most clinical relevance in cholangiocarcinoma are FGFR2 fusions or rearrangements, IDH1 mutations, NTRK gene fusions, BRAF V600E mutations, HER2 amplification or mutations, and RET fusions. Testing also assesses microsatellite instability and tumour mutational burden, which determine eligibility for immunotherapy.
FGFR2 fusions and IDH1 mutations are the two most commonly found actionable changes in intrahepatic cholangiocarcinoma — the type that starts inside the liver. NTRK fusions and BRAF V600E are rare across cancer types but still worth testing for, because approved treatments exist for each.
What targeted treatment is available for each mutation?
For FGFR2 fusions or rearrangements, FGFR inhibitors — including pemigatinib and futibatinib — are included in NCCN and ESMO guidance for intrahepatic cholangiocarcinoma. These drugs are taken as oral tablets and work by blocking the abnormal FGFR2 signal that drives tumour growth.
For IDH1 mutations, ivosidenib is an oral targeted drug included in NCCN and ESMO recommendations. For NTRK fusions, larotrectinib and entrectinib have tumour-agnostic approvals — meaning approval is based on the mutation rather than the cancer type, so they can apply regardless of where the tumour started.
For BRAF V600E, the combination of dabrafenib and trametinib is included in NCCN guidance for bile duct cancer. HER2-directed therapy and RET inhibitors for RET fusions are areas where evidence is still accumulating — your oncologist will tell you what is currently recommended based on your specific result.
What happens when you start targeted therapy?
Most targeted drugs approved for cholangiocarcinoma are oral tablets taken at home rather than infusions in a clinic. You will have regular blood tests and imaging scans to assess whether the disease is responding and to catch side effects early.
Side effects differ between drug classes. FGFR inhibitors can affect phosphate levels in the blood and cause changes to the skin, nails, and eyes. Your team will explain which symptoms to watch for before you start, and regular blood tests allow most changes to be caught early.
How long you stay on treatment depends on how the disease responds, not on a fixed number of cycles. Your oncologist will reassess at each scan and explain the options if the disease stops responding.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
How does targeted therapy work, from biopsy to treatment?
Biopsy and tissue preservation
Tissue from your tumour is collected and preserved — often the block from a biopsy you have already had. If the sample is too small for testing, a repeat biopsy may be needed before genomic profiling can go ahead.
NGS testing
The preserved tissue is sent for comprehensive genomic profiling. This usually takes one to two weeks. One test covers all the mutations relevant to your cancer type, so you do not need separate tests for each marker.
Results review with your oncologist
Your oncologist reviews the report and explains which mutations were found, whether any have a matched targeted drug, and what the published evidence says about response to that treatment.
Treatment planning
If an actionable mutation is found, the appropriate targeted drug is prescribed. If no actionable mutation is identified, your oncologist will discuss chemotherapy, clinical trial options, or other approaches.
Starting therapy and side effect briefing
Most targeted drugs for this cancer type are oral tablets. Before you start, your team explains the dosing schedule, which side effects to watch for, and which symptoms need a same-day call.
Regular monitoring
Scans at regular intervals assess whether the disease is responding. Blood tests between scans check for side effects that can be managed before they become serious.
More questions about targeted therapy for bile duct cancer
What happens if no actionable mutation is found?
Standard first-line treatment for advanced cholangiocarcinoma without an actionable mutation is a chemotherapy combination — gemcitabine-based regimens alongside immunotherapy combinations are now included in major guidelines following recent trial evidence. Not having a targetable mutation does not mean running out of options; it means chemotherapy and immunotherapy are the treatments the evidence supports for your situation. Enrolling in a clinical trial is also worth discussing at this stage, because new targets continue to be identified.
Is NGS testing available in India?
Yes. Several accredited molecular pathology laboratories in India offer comprehensive genomic profiling on tumour tissue, and your oncologist can order the test through your treating centre. Turnaround times and costs vary between providers. Ask your team which laboratory they use and how long results typically take, so you have a realistic timeline before you start waiting. Some centres send samples to specialist reference laboratories for certain tests — your team will tell you if that applies to your case.
Can targeted therapy be combined with chemotherapy?
For most of the mutations described above, targeted drugs were studied alone after prior chemotherapy, and that is how the approvals are structured — as later-line treatments in most cases. Combinations of targeted drugs with chemotherapy are being studied in ongoing trials but are not currently the standard outside a trial setting. If you are interested in trial access, ask your oncologist whether any relevant trials are open at your centre or at a nearby institution.
What happens if the disease stops responding to the targeted drug?
Resistance to targeted therapies in cholangiocarcinoma is a known challenge and an active area of research. When the disease progresses on a targeted drug, options may include switching to a different chemotherapy regimen, enrolling in a clinical trial testing a next-generation inhibitor, or exploring other agents based on mutations identified in a repeat biopsy. A re-biopsy at progression can sometimes reveal new changes that open different treatment options — your oncologist will advise whether that is relevant in your case.
Are these drugs available and affordable in India?
Availability varies. Some targeted drugs included in NCCN and ESMO guidance for cholangiocarcinoma are available in India through licensed distributors; others may require import or compassionate access pathways. Costs for newer targeted agents can be substantial, and coverage under insurance policies or government schemes differs by state and by drug. Your oncologist or a hospital social worker can advise on what is accessible for your situation, including whether a clinical trial might give you access to an agent not yet commercially available.
Should we get a second opinion on the NGS report?
It is reasonable to ask for a second opinion on the interpretation of a complex NGS report, particularly if the result is borderline, the mutation is rare, or the recommended treatment is one your oncologist has not used before. Reputable NGS laboratories use validated assays, so the raw result is usually reliable; the interpretation — which mutations are clinically actionable for your specific cancer type — is where expert review adds most value. A second opinion from an oncologist with specialist experience in biliary tract cancers can help you feel confident in the plan.
Did you know?
FGFR2 fusions and rearrangements occur almost exclusively in intrahepatic cholangiocarcinoma — the type that starts inside the liver — and are rarely found in gallbladder cancer or in bile duct cancers that arise outside the liver.
This means the specific location of your tumour directly influences which mutations are most likely to be present, and why a detailed pathology report matters before the genomic test is ordered.
Source: ESMO Clinical Practice Guidelines for Biliary Tract Cancer
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Is targeted therapy used in early-stage bile duct cancer?
Current NCCN and ESMO guidance for targeted therapy in cholangiocarcinoma is primarily for advanced or metastatic disease. In early-stage disease, surgery is the treatment of choice where it is possible, and the role of targeted therapy in earlier settings is not established outside clinical trials. If surgery has been recommended for you, ask your oncologist whether molecular testing is advised before or after the operation, as research in this area is ongoing.
How do I get NGS testing started?
Ask your oncologist to order comprehensive genomic profiling on your tumour tissue. In most cases the laboratory uses the tissue block from your original biopsy, so you do not need a new procedure. Your oncologist submits the sample with a request form specifying your cancer type, so the laboratory knows which markers to include. If you have had previous biopsies at different centres, make sure your oncologist has access to the most recent tissue block — older samples may not reflect the current biology of the disease.
What is the difference between an FGFR2 fusion and an FGFR2 mutation?
An FGFR2 fusion — also called a rearrangement — is a structural change where a segment of the FGFR2 gene joins to a different gene, creating an abnormal protein that drives tumour growth. This is the change that FGFR inhibitors such as pemigatinib and futibatinib are approved to target. FGFR2 point mutations are different changes in the same gene and are not the same target. Your NGS report will specify the exact change found, and your oncologist will explain whether it qualifies for a targeted drug.
Can targeted therapy work after chemotherapy has stopped working?
Yes — for most of the approved targeted drugs in cholangiocarcinoma, the clinical trials that established their use enrolled patients who had already received prior chemotherapy. This means the approvals are specifically designed for patients in whom chemotherapy is no longer working. If you are currently on first-line chemotherapy and have not yet had NGS testing done, it is worth pursuing that now so results are ready when your oncologist needs to plan the next step.
Are there clinical trials for bile duct cancer in India?
Clinical trials for cholangiocarcinoma are open at several cancer centres in India, including trials of next-generation targeted agents and novel combinations. Targeted therapy for cholangiocarcinoma is administered as day care at CION centres, and response-assessment imaging such as PET-CT is coordinated with partner imaging centres. Ask your oncologist whether any trials relevant to your mutation are open at your treating centre — participating can provide access to drugs not yet commercially available in India.
What should I ask at my next appointment?
Ask four things: whether comprehensive genomic profiling has been ordered on your tumour tissue and when results are expected; which mutations were found and whether any have a matched targeted drug; if no actionable mutation was found, what the recommended treatment is and what it aims to achieve; and whether any clinical trials are open that are relevant to your result. Write the answers down — these conversations are difficult to recall accurately when you are worried. It is reasonable to ask for a copy of your NGS report in writing.